\-\ Texto\\:\\ \ \(0\)\
\-\ results\\:\ \(5\)\
\-\ \\	prior\\ to\\ mass\\ work\\-up\\,\\ the\\ following\\ lab\\ data\\ was\\ collected\\:\ \(0\)\
\-\ wbc\\ 5\\.9\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ glu\\ \\ 91\ \(0\)\
\-\ rbc\\ 4\\.44\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ bun\\ 10\ \(0\)\
\-\ hgb\\ 13\\.7\\	\\	\\ \\ \\ \\ \\ \\ \\ \\ creat\\ 1\\.0\ \(0\)\
\-\ hct\\ 39\\.1\\	\\	\\ \\ \\ \\ \\ \\ \\ \\ na\\+\\ \\ 140\ \(0\)\
\-\ mcv\\ 88\\	\\	\\ \\ \\ \\ \\ \\ \\ \\ k\\+\\ \\ \\ \\ \\ 3\\.9\ \(0\)\
\-\ plt\\ 261\\	\\	\\ \\ \\ \\ \\ \\ \\ \\ cl\\-\\ \\ \\ 107\ \(0\)\
\-\ neut\\#\\ \\ 3\\.70\\;\\ lymph\\#\\ 1\\.10\\;\\ mono\\#\\ 0\\.50\\;\\ eos\\#\\ 0\\.70\ \(0\)\
\-\ afp\\ 1\\.0\\ \\ \\(0\\.0\\-6\\.1\\)\ \(0\)\
\-\ treatment\\:\ \(3\)\
\-\ \\ \\ therapy\\ is\\ based\\ on\\ the\\ presenting\\ stage\\ of\\ the\\ disease\\.\\ \\(stages\\ discussed\\ in\\ \\"discussion\\)\\.\ \(0\)\
\-\ stage\\ ia\\,\\ iia\\:\\ radiation\\ therapy\\ or\\ combination\\ radiation\\ and\\ chemotherapy\ \(0\)\
\-\ stage\\ iiia\\:\\ radiation\\ or\\ chemotherapy\ \(0\)\
\-\ stage\\ iv\\:\\ combination\\ chemotherapy\\.\ \(0\)\
\-\ when\\ b\\ symptoms\\ are\\ present\\,\\ chemotherapy\\ is\\ recommended\\ regardless\\ of\\ stage\\.\ \(0\)\
\-\ survival\\ rates\\ by\\ stage\\:\ \(0\)\
\-\ stage\\	5\\-year\\ relative\\ survival\\ rate\ \(0\)\
\-\ i\\	90\\%\\ to\\ 95\\%\ \(0\)\
\-\ ii\\	90\\%\\ to\\ 95\\%\ \(0\)\
\-\ iii\\	85\\%\\ to\\ 90\\%\ \(0\)\
\-\ iv\\	about\\ 80\\%\ \(0\)\
\-\ chest\\ x\\-ray\\ revealed\\ r\\ sided\\ medistinal\\ mass\\ without\\ evidence\\ of\\ any\\ other\\ acute\\ cardiopulmonary\\ process\\ \\.\ \(0\)\
\-\ \\ \\ \\ subsequently\\,\\ a\\ biopsy\\ of\\ the\\ mediastinal\\ mass\\ was\\ performed\\.\\ initial\\ frozen\\ section\\ revealed\\ fibrous\\ tussue\\ with\\ lymphoid\\ population\\.\ \(0\)\
\-\ final\\ diagnosis\\:\\ \ \(0\)\
\-\ hodgkin\\‚\\Ä\\ôs\\ lymphoma\\,\\ nodular\\ sclerosing\\ cell\\ type\ \(0\)\
\-\ \\‚\\Ä\\úsections\\ show\\ thick\\ fibrotic\\ bands\\ with\\ small\\ benign\\-appearing\\ lymphocytes\\ and\\ occasional\\ eosinophils\\.\\ additionally\\,\\ there\\ are\\ widely\\ scattered\\ large\\ atypical\\ cells\\ with\\ prominent\\ nucleoli\\.\\ these\\ cells\\ are\\ positive\\ for\\ cd15\\ and\\ cd30\\;\\ negative\\ for\\ lca\\,\\ cd20\\,\\ and\\ cd3\\.\\‚\\Ä\\ù\ \(0\)\
\-\ hodgkin\\'s\\ lymphoma\ \(0\)\
\-\ malignancy\ \(256\)\
\-\ aneurysm\ \(644\)\
\-\ infectious\\ etiology\ \(7\)\
\-\ trauma\ \(1087\)\
\-\ intro\\:\\ 21\\ yo\\ white\\ female\\ presented\\ to\\ her\\ physician\\ with\\ an\\ unknown\\ chief\\ complaint\\.\\ \\ a\\ chest\\ x\\-ray\\ was\\ done\\ revealing\\ an\\ anterior\\ r\\ sided\\ mediastinal\\ mass\\.\ \(0\)\
\-\ discussion\\:\ \(1\)\
\-\ \\	hodgkin\\‚\\Ä\\ôs\\ lymphoma\\ is\\ a\\ malignancy\\ of\\ the\\ lymphatic\\ system\\ that\\ usually\\ presents\\ with\\ cervical\\ adenopathy\\.\\ its\\ incidence\\ is\\ estimated\\ by\\ the\\ american\\ cancer\\ society\\ as\\ 7\\,880\\ cases\\ of\\ hodgkin\\'s\\ lymphoma\\ \\(4\\,330\\ men\\ and\\ 3\\,550\\ women\\)\\ diagnosed\\ in\\ the\\ u\\.s\\.\\ in\\ 2004\\,\\ less\\ than\\ 1\\%\\ of\\ all\\ cancer\\ diagnoses\\.\\ \\ \\ approximately\\ 131\\,279\\ members\\ of\\ the\\ u\\.s\\.\\ population\\ are\\ living\\ with\\ hodgkin\\'s\\ lymphoma\\.\\ \\ 85\\-90\\%\\ of\\ hodgkin\\'s\\ occurs\\ in\\ adults\\,\\ 10\\ to\\ 15\\%\\ in\\ children\\.\\ \\ it\\ is\\ more\\ common\\,\\ though\\,\\ in\\ 2\\ age\\ groups\\:\\ early\\ adulthood\\ \\(age\\ 15\\-40\\,\\ usually\\ 25\\-30\\)\\ and\\ late\\ adulthood\\ \\(after\\ age\\ 55\\)\\.\\ hodgkin\\'s\\ is\\ rare\\ before\\ 5\\ years\\ of\\ age\\.\ \(0\)\
\-\ \\	lymphoma\\ of\\ any\\ type\\ is\\ usually\\ diagnosed\\ by\\ biopsy\\ of\\ an\\ enlarged\\ lymph\\ node\\ with\\ identification\\ of\\ specific\\ reed\\-sternberg\\ cells\\ on\\ examination\\.\ \(0\)\
\-\ types\\ of\\ hodgkin\\‚\\Ä\\ôs\\ lymphoma\\:\ \(0\)\
\-\ \\‚\\Ä\\¢\\	nodular\\ sclerosis\\ \\(ns\\)\\.\\ the\\ lymph\\ nodes\\ in\\ the\\ lower\\ neck\\,\\ chest\\ and\\ collarbone\\ usually\\ contain\\ normal\\ and\\ reactive\\ lymphocytes\\ and\\ reed\\-sternberg\\ cells\\ separated\\ by\\ bands\\ of\\ scar\\-like\\ tissues\\.\\ ns\\ accounts\\ for\\ 60\\-70\\%\\ of\\ hodgkin\\'s\\ cases\\.\\ ns\\ appears\\ to\\ account\\ for\\ the\\ increase\\ in\\ hodgkin\\'s\\ cases\\ in\\ recent\\ years\\ \ \(0\)\
\-\ \\‚\\Ä\\¢\\	lymphocyte\\ predominance\\ \\(lp\\)\\.\\ the\\ lymph\\ nodes\\ are\\ composed\\ largely\\ of\\ reactive\\ lymphocytes\\ and\\ malignant\\ l\\&h\\ cells\\ which\\ have\\ a\\ \\"popcorn\\"\\ appearance\\ and\\ very\\ few\\ reed\\-sternberg\\ cells\\.\\ lp\\ accounts\\ for\\ 5\\%\\ of\\ hodgkin\\'s\\ cases\\ and\\ affects\\ more\\ men\\ than\\ women\\.\\ \ \(0\)\
\-\ \\‚\\Ä\\¢\\	mixed\\ cellularity\\ \\(mc\\)\\.\\ the\\ lymph\\ nodes\\ usually\\ contain\\ reed\\-sternberg\\ cells\\ and\\ inflammatory\\ cells\\.\\ mc\\ accounts\\ for\\ 20\\-30\\%\\ of\\ hodgkin\\'s\\ cases\\.\\ \ \(0\)\
\-\ \\‚\\Ä\\¢\\	lymphocyte\\ depleted\\ \\(ld\\)\\.\\ there\\ are\\ two\\ different\\ variations\\ of\\ this\\ classification\\:\\ one\\ with\\ sheets\\ of\\ differing\\ malignant\\ cells\\;\\ the\\ other\\ with\\ few\\ reed\\-sternberg\\ cells\\ and\\ lymphocytes\\ with\\ scar\\-like\\ tissue\\.\\ accounts\\ for\\ about\\ 5\\%\\ of\\ hodgkin\\'s\\ cases\\.\\ \ \(0\)\
\-\ \\‚\\Ä\\¢\\	nodular\\ lymphocyte\\ predominant\\ \\(nlp\\)\\ hodgkin\\'s\\ lymphoma\\ \\-\\ while\\ the\\ 4\\ types\\ above\\ are\\ \\"classical\\"\\ types\\,\\ nlp\\ is\\ in\\ a\\ category\\ of\\ its\\ own\\.\\ typical\\ reed\\-sternberg\\ cells\\ are\\ rare\\ to\\ non\\-existent\\;\\ instead\\ variants\\ called\\ l\\ \\&\\ h\\ cells\\ \\(colloquially\\ \\"popcorn\\ cells\\"\\)\\ are\\ seen\\.\\ \\ \ \(0\)\
\-\ staging\\ is\\ organized\\ into\\ 4\\ categories\\:\ \(0\)\
\-\ stage\\ i\\:\\ \\ \\ \\ \\ disease\\ localized\\ to\\ single\\ lymph\\ node\\ or\\ group\ \(0\)\
\-\ stage\\ ii\\:\\ \\ \\ disease\\ involving\\ more\\ than\\ one\\ lymph\\ node\\ or\\ group\\,\\ but\\ confined\\ to\\ one\\ side\\ \ \(0\)\
\-\ \\	\\ \\ \\ \\ \\ of\\ the\\ diaphragm\ \(1\)\
\-\ stage\\ iii\\:\\ \\ disease\\ in\\ the\\ lymph\\ nodes\\ or\\ the\\ spleen\\ and\\ occurs\\ of\\ both\\ sides\\ of\\ the\\ \ \(0\)\
\-\ \\	\\ \\ \\ \\ \\ diaphragm\ \(1\)\
\-\ stage\\ iv\\:\\ \\ disease\\ involving\\ the\\ liver\\,\\ lung\\,\\ skin\\,\\ or\\ bone\\ marrow\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ hodgkin\\:\\ 0\\.09902413839760671\ \(0\)\
\-\ reed\\-sternberg\\:\\ 0\\.061571059590146714\ \(0\)\
\-\ cells\\:\\ 0\\.05923378593610368\ \(0\)\
\-\ stage\\:\\ 0\\.053318322763579534\ \(0\)\
\-\ \\%\\:\\ 0\\.03710970008888844\ \(0\)\
\-\ lymph\\:\\ 0\\.0366972596696239\ \(0\)\
\-\ ns\\:\\ 0\\.030785529795073357\ \(0\)\
\-\ lymphocytes\\:\\ 0\\.029360008287032814\ \(0\)\
\-\ accounts\\:\\ 0\\.02862516606107102\ \(0\)\
\-\ \\'s\\:\\ 0\\.027559192555900926\ \(0\)\
\-\ \\:\\:\\ 0\\.02705445038275528\ \(0\)\
\-\ lymphocyte\\:\\ 0\\.02640276800517398\ \(0\)\
\-\ lymphoma\\:\\ 0\\.025980836536058358\ \(0\)\
\-\ scar\\-like\\:\\ 0\\.023445527723315155\ \(0\)\
\-\ cases\\:\\ 0\\.022713916467934567\ \(0\)\
\-\ nodes\\:\\ 0\\.020530273225347007\ \(0\)\
\-\ nlp\\:\\ 0\\.020523686530048903\ \(0\)\
\-\ \\#\\:\\ 0\\.017828120313515362\ \(0\)\
\-\ types\\:\\ 0\\.0173982890733231\ \(0\)\
\-\ u\\.s\\:\\ 0\\.01732163119939482\ \(0\)\
\-\ usually\\:\\ 0\\.01725351232624175\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.01629226481457907\ \(0\)\
\-\ \\;\\:\\ 0\\.01616027543978133\ \(0\)\
\-\ 90\\:\\ 0\\.016069255377065633\ \(0\)\
\-\ lp\\:\\ 0\\.01591038585082522\ \(0\)\
\-\ popcorn\\:\\ 0\\.01591038585082522\ \(0\)\
\-\ node\\:\\ 0\\.01559937624545772\ \(0\)\
\-\ adulthood\\:\\ 0\\.01522467013459623\ \(0\)\
\-\ nodular\\:\\ 0\\.01429950720922305\ \(0\)\
\-\ 1\\.0\\:\\ 0\\.014146305485372388\ \(0\)\
\-\ are\\:\\ 0\\.01394130964463619\ \(0\)\
\-\ age\\:\\ 0\\.013834629391193119\ \(0\)\
\-\ bands\\:\\ 0\\.013569006269314336\ \(0\)\
\-\ mc\\:\\ 0\\.013321425356904731\ \(0\)\
\-\ men\\:\\ 0\\.012836527599473999\ \(0\)\
\-\ 95\\:\\ 0\\.01278772669876071\ \(0\)\
\-\ contain\\:\\ 0\\.012556313462086164\ \(0\)\
\-\ iv\\:\\ 0\\.012440525016467129\ \(0\)\
\-\ diaphragm\\:\\ 0\\.012223432762740401\ \(0\)\
\-\ survival\\:\\ 0\\.012184606168535209\ \(0\)\
\-\ h\\:\\ 0\\.011962846570293053\ \(0\)\
\-\ population\\:\\ 0\\.011858536162970496\ \(0\)\
\-\ group\\:\\ 0\\.011824655775264566\ \(0\)\
\-\ 4\\.44\\:\\ 0\\.011722763861657578\ \(0\)\
\-\ 261\\:\\ 0\\.011722763861657578\ \(0\)\
\-\ 3\\.70\\:\\ 0\\.011722763861657578\ \(0\)\
\-\ 1\\.10\\:\\ 0\\.011722763861657578\ \(0\)\
\-\ 0\\.50\\:\\ 0\\.011722763861657578\ \(0\)\
\-\ 0\\.70\\:\\ 0\\.011722763861657578\ \(0\)\
\-\ medistinal\\:\\ 0\\.011722763861657578\ \(0\)\
\-\ tussue\\:\\ 0\\.011722763861657578\ \(0\)\
\-\ cd15\\:\\ 0\\.011722763861657578\ \(0\)\
\-\ cd30\\:\\ 0\\.011722763861657578\ \(0\)\
\-\ cd3\\.\\:\\ 0\\.011722763861657578\ \(0\)\
\-\ intro\\:\\ 0\\.011722763861657578\ \(0\)\
\-\ 7\\,880\\:\\ 0\\.011722763861657578\ \(0\)\
\-\ 4\\,330\\:\\ 0\\.011722763861657578\ \(0\)\
\-\ 3\\,550\\:\\ 0\\.011722763861657578\ \(0\)\
\-\ 131\\,279\\:\\ 0\\.011722763861657578\ \(0\)\
\-\ collarbone\\:\\ 0\\.011722763861657578\ \(0\)\
\-\ ld\\:\\ 0\\.011722763861657578\ \(0\)\
\-\ colloquially\\:\\ 0\\.011722763861657578\ \(0\)\
\-\ combination\\:\\ 0\\.011448560950663959\ \(0\)\
\-\ radiation\\:\\ 0\\.011187172538147617\ \(0\)\
\-\ \\`\\`\\:\\ 0\\.01117093105123307\ \(0\)\
\-\ women\\:\\ 0\\.011042764175144763\ \(0\)\
\-\ 0\\.0\\-6\\.1\\:\\ 0\\.010801025589636373\ \(0\)\
\-\ ia\\:\\ 0\\.010801025589636373\ \(0\)\
\-\ lca\\:\\ 0\\.010801025589636373\ \(0\)\
\-\ non\\-existent\\:\\ 0\\.010801025589636373\ \(0\)\
\-\ reactive\\:\\ 0\\.010757536700800088\ \(0\)\
\-\ iii\\:\\ 0\\.010668876008599046\ \(0\)\
\-\ discussion\\:\\ 0\\.010647165076048086\ \(0\)\
\-\ \\(\\:\\ 0\\.010566461421120301\ \(0\)\
\-\ \\)\\:\\ 0\\.010437386453785048\ \(0\)\
\-\ \\‚\\Ä\\¢\\:\\ 0\\.010418978401568404\ \(0\)\
\-\ l\\:\\ 0\\.01036047206951695\ \(0\)\
\-\ r\\:\\ 0\\.010321926837329272\ \(0\)\
\-\ 39\\.1\\:\\ 0\\.010261843265024452\ \(0\)\
\-\ k\\+\\:\\ 0\\.010261843265024452\ \(0\)\
\-\ depleted\\:\\ 0\\.010261843265024452\ \(0\)\
\-\ x\\-ray\\:\\ 0\\.010246472855602635\ \(0\)\
\-\ few\\:\\ 0\\.010227939160613025\ \(0\)\
\-\ \\‚\\Ä\\ô\\:\\ 0\\.010188936461351552\ \(0\)\
\-\ 5\\:\\ 0\\.009974044238474054\ \(0\)\
\-\ benign\\-appearing\\:\\ 0\\.009879287317615169\ \(0\)\
\-\ 85\\-90\\:\\ 0\\.009879287317615169\ \(0\)\
\-\ 15\\-40\\:\\ 0\\.009879287317615169\ \(0\)\
\-\ differing\\:\\ 0\\.009879287317615169\ \(0\)\
\-\ ii\\:\\ 0\\.009802180077243152\ \(0\)\
\-\ s\\:\\ 0\\.009776998671999682\ \(0\)\
\-\ mediastinal\\:\\ 0\\.009649288877993998\ \(0\)\
\-\ 13\\.7\\:\\ 0\\.009582553871718615\ \(0\)\
\-\ iiia\\:\\ 0\\.009582553871718615\ \(0\)\
\-\ i\\:\\ 0\\.009394453976671569\ \(0\)\
\-\ sheets\\:\\ 0\\.00934010499300325\ \(0\)\
\-\ occurs\\:\\ 0\\.009327794485545993\ \(0\)\
\-\ disease\\:\\ 0\\.00928681875808314\ \(0\)\
\-\ one\\:\\ 0\\.009238290092994591\ \(0\)\
\-\ collected\\:\\ 0\\.009135117386849979\ \(0\)\
\-\ glu\\:\\ 0\\.009135117386849979\ \(0\)\
\-\ 107\\:\\ 0\\.009135117386849979\ \(0\)\
\-\ neut\\:\\ 0\\.009135117386849979\ \(0\)\
\-\ cd20\\:\\ 0\\.009135117386849979\ \(0\)\
\-\ 25\\-30\\:\\ 0\\.009135117386849979\ \(0\)\
\-\ 60\\-70\\:\\ 0\\.009135117386849979\ \(0\)\
\-\ variations\\:\\ 0\\.009135117386849979\ \(0\)\
\-\ 5\\.9\\:\\ 0\\.008957549045593965\ \(0\)\
\-\ eos\\:\\ 0\\.008957549045593965\ \(0\)\
\-\ iia\\:\\ 0\\.008957549045593965\ \(0\)\
\-\ nucleoli\\:\\ 0\\.008957549045593965\ \(0\)\
\-\ than\\:\\ 0\\.008932375751003752\ \(0\)\
\-\ rare\\:\\ 0\\.008825399464556639\ \(0\)\
\-\ creat\\:\\ 0\\.008800922668391328\ \(0\)\
\-\ cl\\-\\:\\ 0\\.008800922668391328\ \(0\)\
\-\ organized\\:\\ 0\\.008800922668391328\ \(0\)\
\-\ malignancy\\:\\ 0\\.008782153398408286\ \(0\)\
\-\ about\\:\\ 0\\.008760791239638967\ \(0\)\
\-\ na\\+\\:\\ 0\\.00866081559969741\ \(0\)\
\-\ mono\\:\\ 0\\.00866081559969741\ \(0\)\
\-\ cellularity\\:\\ 0\\.00866081559969741\ \(0\)\
\-\ its\\:\\ 0\\.008575881498552238\ \(0\)\
\-\ frozen\\:\\ 0\\.008534073339319319\ \(0\)\
\-\ more\\:\\ 0\\.008525969319064493\ \(0\)\
\-\ sided\\:\\ 0\\.008402996311560227\ \(0\)\
\-\ diagnosed\\:\\ 0\\.008356902012752673\ \(0\)\
\-\ 5\\-year\\:\\ 0\\.008311926950139575\ \(0\)\
\-\ variants\\:\\ 0\\.008311926950139575\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.00821708577918448\ \(0\)\
\-\ malignant\\:\\ 0\\.008214549671221545\ \(0\)\
\-\ chest\\:\\ 0\\.00815716356405925\ \(0\)\
\-\ 3\\.9\\:\\ 0\\.008121633275085489\ \(0\)\
\-\ fibrotic\\:\\ 0\\.008121633275085489\ \(0\)\
\-\ eosinophils\\:\\ 0\\.008121633275085489\ \(0\)\
\-\ society\\:\\ 0\\.008121633275085489\ \(0\)\
\-\ biopsy\\:\\ 0\\.008063013940523299\ \(0\)\
\-\ 140\\:\\ 0\\.008035810773572762\ \(0\)\
\-\ lymphoid\\:\\ 0\\.008035810773572762\ \(0\)\
\-\ members\\:\\ 0\\.008035810773572762\ \(0\)\
\-\ classical\\:\\ 0\\.008035810773572762\ \(0\)\
\-\ or\\:\\ 0\\.007990872997050858\ \(0\)\
\-\ \\&\\:\\ 0\\.007982414606759126\ \(0\)\
\-\ involving\\:\\ 0\\.00797448740426408\ \(0\)\
\-\ regardless\\:\\ 0\\.00795519292541261\ \(0\)\
\-\ 20\\-30\\:\\ 0\\.007879184396370125\ \(0\)\
\-\ 91\\:\\ 0\\.007807286495744758\ \(0\)\
\-\ categories\\:\\ 0\\.007739077327676206\ \(0\)\
\-\ mcv\\:\\ 0\\.007674196790216855\ \(0\)\
\-\ separated\\:\\ 0\\.007674196790216855\ \(0\)\
\-\ 10\\:\\ 0\\.007661234649858804\ \(0\)\
\-\ type\\:\\ 0\\.007661234649858804\ \(0\)\
\-\ cardiopulmonary\\:\\ 0\\.007612335067298115\ \(0\)\
\-\ by\\:\\ 0\\.007568462251302525\ \(0\)\
\-\ sections\\:\\ 0\\.007553223680900729\ \(0\)\
\-\ lymphatic\\:\\ 0\\.007553223680900729\ \(0\)\
\-\ living\\:\\ 0\\.007553223680900729\ \(0\)\
\-\ widely\\:\\ 0\\.007496628448960841\ \(0\)\
\-\ cancer\\:\\ 0\\.007471184213736078\ \(0\)\
\-\ 88\\:\\ 0\\.007442343881779651\ \(0\)\
\-\ category\\:\\ 0\\.007442343881779651\ \(0\)\
\-\ largely\\:\\ 0\\.007390188678118372\ \(0\)\
\-\ revealing\\:\\ 0\\.0073400020717582035\ \(0\)\
\-\ predominant\\:\\ 0\\.0073400020717582035\ \(0\)\
\-\ revealed\\:\\ 0\\.007293813536877907\ \(0\)\
\-\ groups\\:\\ 0\\.007291640842807571\ \(0\)\
\-\ own\\:\\ 0\\.007291640842807571\ \(0\)\
\-\ plt\\:\\ 0\\.00724497685369684\ \(0\)\
\-\ any\\:\\ 0\\.007156476151788015\ \(0\)\
\-\ identification\\:\\ 0\\.007156291515267755\ \(0\)\
\-\ instead\\:\\ 0\\.007156291515267755\ \(0\)\
\-\ predominance\\:\\ 0\\.007114072501551557\ \(0\)\
\-\ sides\\:\\ 0\\.007073152742686194\ \(0\)\
\-\ afp\\:\\ 0\\.006994907396911016\ \(0\)\
\-\ composed\\:\\ 0\\.006957446124348921\ \(0\)\
\-\ confined\\:\\ 0\\.006851006353506452\ \(0\)\
\-\ \\,\\:\\ 0\\.006839748995782526\ \(0\)\
\-\ stages\\:\\ 0\\.006817339055655002\ \(0\)\
\-\ for\\:\\ 0\\.006786910958110379\ \(0\)\
\-\ is\\:\\ 0\\.006729543890242727\ \(0\)\
\-\ sclerosing\\:\\ 0\\.006721167963128903\ \(0\)\
\-\ chief\\:\\ 0\\.006721167963128903\ \(0\)\
\-\ diagnoses\\:\\ 0\\.006721167963128903\ \(0\)\
\-\ years\\:\\ 0\\.006673518981432134\ \(0\)\
\-\ rates\\:\\ 0\\.006602886731723989\ \(0\)\
\-\ estimated\\:\\ 0\\.006574890176939637\ \(0\)\
\-\ rbc\\:\\ 0\\.006547470912042382\ \(0\)\
\-\ staging\\:\\ 0\\.006547470912042382\ \(0\)\
\-\ classification\\:\\ 0\\.006494272328779484\ \(0\)\
\-\ affects\\:\\ 0\\.006468450406097168\ \(0\)\
\-\ work\\-up\\:\\ 0\\.006418263799736999\ \(0\)\
\-\ account\\:\\ 0\\.006418263799736999\ \(0\)\
\-\ 85\\:\\ 0\\.006346365899111633\ \(0\)\
\-\ 4\\:\\ 0\\.006332372088242141\ \(0\)\
\-\ hgb\\:\\ 0\\.0063232385816756375\ \(0\)\
\-\ mass\\:\\ 0\\.006321601100784917\ \(0\)\
\-\ bun\\:\\ 0\\.006278156731043082\ \(0\)\
\-\ discussed\\:\\ 0\\.006213276193583731\ \(0\)\
\-\ hct\\:\\ 0\\.006171716960200612\ \(0\)\
\-\ in\\:\\ 0\\.006164055228115431\ \(0\)\
\-\ data\\:\\ 0\\.00615141447066499\ \(0\)\
\-\ final\\:\\ 0\\.006131417293318528\ \(0\)\
\-\ 2004\\:\\ 0\\.006111716381370201\ \(0\)\
\-\ spleen\\:\\ 0\\.006111716381370201\ \(0\)\
\-\ section\\:\\ 0\\.0060923030842676045\ \(0\)\
\-\ therapy\\:\\ 0\\.006076172330427162\ \(0\)\
\-\ occasional\\:\\ 0\\.0059992730462265\ \(0\)\
\-\ thick\\:\\ 0\\.00596380995170235\ \(0\)\
\-\ called\\:\\ 0\\.00596380995170235\ \(0\)\
\-\ late\\:\\ 0\\.005912327887632283\ \(0\)\
\-\ adults\\:\\ 0\\.0057994296911077\ \(0\)\
\-\ to\\:\\ 0\\.005679097186741838\ \(0\)\
\-\ different\\:\\ 0\\.005625732640021178\ \(0\)\
\-\ lab\\:\\ 0\\.005559560419862849\ \(0\)\
\-\ localized\\:\\ 0\\.005533986800277893\ \(0\)\
\-\ 55\\:\\ 0\\.005508895730724191\ \(0\)\
\-\ relative\\:\\ 0\\.005413013690961766\ \(0\)\
\-\ american\\:\\ 0\\.005413013690961766\ \(0\)\
\-\ b\\:\\ 0\\.005356418459021879\ \(0\)\
\-\ physician\\:\\ 0\\.005356418459021879\ \(0\)\
\-\ 80\\:\\ 0\\.005345382816981059\ \(0\)\
\-\ scattered\\:\\ 0\\.005291537921562527\ \(0\)\
\-\ though\\:\\ 0\\.00527059595750915\ \(0\)\
\-\ complaint\\:\\ 0\\.005249978688179409\ \(0\)\
\-\ other\\:\\ 0\\.0052384003954852355\ \(0\)\
\-\ incidence\\:\\ 0\\.0052096790212973225\ \(0\)\
\-\ subsequently\\:\\ 0\\.005151430852868609\ \(0\)\
\-\ 21\\:\\ 0\\.005141966135090864\ \(0\)\
\-\ adenopathy\\:\\ 0\\.005059685013125322\ \(0\)\
\-\ marrow\\:\\ 0\\.004999032737524189\ \(0\)\
\-\ mixed\\:\\ 0\\.004990589615611079\ \(0\)\
\-\ additionally\\:\\ 0\\.004924907760119621\ \(0\)\
\-\ atypical\\:\\ 0\\.004924907760119621\ \(0\)\
\-\ children\\:\\ 0\\.004908981974153243\ \(0\)\
\-\ infectious\\:\\ 0\\.004885445302478508\ \(0\)\
\-\ etiology\\:\\ 0\\.004809868873272171\ \(0\)\
\-\ before\\:\\ 0\\.004809868873272171\ \(0\)\
\-\ increase\\:\\ 0\\.0047665024030743505\ \(0\)\
\-\ an\\:\\ 0\\.004714088554327379\ \(0\)\
\-\ recommended\\:\\ 0\\.004710796363567488\ \(0\)\
\-\ done\\:\\ 0\\.004710796363567488\ \(0\)\
\-\ specific\\:\\ 0\\.004697226988335784\ \(0\)\
\-\ prominent\\:\\ 0\\.004663897242772996\ \(0\)\
\-\ tissues\\:\\ 0\\.004663897242772996\ \(0\)\
\-\ presenting\\:\\ 0\\.00463138248763448\ \(0\)\
\-\ single\\:\\ 0\\.004605931237354297\ \(0\)\
\-\ fibrous\\:\\ 0\\.004593385981724831\ \(0\)\
\-\ results\\:\\ 0\\.004587157458702988\ \(0\)\
\-\ typical\\:\\ 0\\.004556445072007975\ \(0\)\
\-\ 15\\:\\ 0\\.004532375867694653\ \(0\)\
\-\ aneurysm\\:\\ 0\\.004491275418940562\ \(0\)\
\-\ system\\:\\ 0\\.004474042513830848\ \(0\)\
\-\ unknown\\:\\ 0\\.0044346801870006735\ \(0\)\
\-\ rate\\:\\ 0\\.004429150918185961\ \(0\)\
\-\ process\\:\\ 0\\.004375087080897226\ \(0\)\
\-\ skin\\:\\ 0\\.004364533158562471\ \(0\)\
\-\ based\\:\\ 0\\.004333364843440107\ \(0\)\
\-\ \\‚\\Ä\\ú\\:\\ 0\\.004244017177897819\ \(0\)\
\-\ appears\\:\\ 0\\.004229692580847405\ \(0\)\
\-\ \\‚\\Ä\\ù\\:\\ 0\\.00422022786306966\ \(0\)\
\-\ above\\:\\ 0\\.004164812043388054\ \(0\)\
\-\ early\\:\\ 0\\.004155796502184093\ \(0\)\
\-\ wbc\\:\\ 0\\.004142386769382728\ \(0\)\
\-\ cervical\\:\\ 0\\.004129110913020782\ \(0\)\
\-\ very\\:\\ 0\\.004124714918161076\ \(0\)\
\-\ sclerosis\\:\\ 0\\.004081536214662692\ \(0\)\
\-\ of\\:\\ 0\\.004028056942483643\ \(0\)\
\-\ was\\:\\ 0\\.003942596498192899\ \(0\)\
\-\ inflammatory\\:\\ 0\\.003940579713021308\ \(0\)\
\-\ side\\:\\ 0\\.003936763965111796\ \(0\)\
\-\ liver\\:\\ 0\\.00391784775376692\ \(0\)\
\-\ enlarged\\:\\ 0\\.003877155678702136\ \(0\)\
\-\ less\\:\\ 0\\.0038483244738333543\ \(0\)\
\-\ recent\\:\\ 0\\.003820105118138028\ \(0\)\
\-\ white\\:\\ 0\\.0037687556020106617\ \(0\)\
\-\ initial\\:\\ 0\\.0037654017862756755\ \(0\)\
\-\ positive\\:\\ 0\\.003687347859420368\ \(0\)\
\-\ the\\:\\ 0\\.0036768426782879202\ \(0\)\
\-\ and\\:\\ 0\\.0035906051675309533\ \(0\)\
\-\ while\\:\\ 0\\.003575331435973821\ \(0\)\
\-\ examination\\:\\ 0\\.0035324774407906453\ \(0\)\
\-\ approximately\\:\\ 0\\.003515715194887743\ \(0\)\
\-\ show\\:\\ 0\\.0034882392745899282\ \(0\)\
\-\ yo\\:\\ 0\\.0034193504299238854\ \(0\)\
\-\ her\\:\\ 0\\.003416770822453372\ \(0\)\
\-\ negative\\:\\ 0\\.0033937768103389286\ \(0\)\
\-\ there\\:\\ 0\\.0033822222246409272\ \(0\)\
\-\ neck\\:\\ 0\\.003336759490716067\ \(0\)\
\-\ lung\\:\\ 0\\.0032914350003174814\ \(0\)\
\-\ when\\:\\ 0\\.003254429837255327\ \(0\)\
\-\ two\\:\\ 0\\.003254429837255327\ \(0\)\
\-\ appearance\\:\\ 0\\.003249875766934364\ \(0\)\
\-\ following\\:\\ 0\\.003225103400134506\ \(0\)\
\-\ all\\:\\ 0\\.003213994001903312\ \(0\)\
\-\ performed\\:\\ 0\\.0031683222489724988\ \(0\)\
\-\ trauma\\:\\ 0\\.0031077244438270334\ \(0\)\
\-\ presented\\:\\ 0\\.0030975500465723524\ \(0\)\
\-\ cell\\:\\ 0\\.0030694690313583595\ \(0\)\
\-\ evidence\\:\\ 0\\.0029793119459665925\ \(0\)\
\-\ common\\:\\ 0\\.0029737595903675494\ \(0\)\
\-\ these\\:\\ 0\\.00295724028185883\ \(0\)\
\-\ anterior\\:\\ 0\\.002926586201812151\ \(0\)\
\-\ prior\\:\\ 0\\.0029177031545244195\ \(0\)\
\-\ both\\:\\ 0\\.0029018616897421826\ \(0\)\
\-\ symptoms\\:\\ 0\\.0028319913256624188\ \(0\)\
\-\ bone\\:\\ 0\\.0028237163317285504\ \(0\)\
\-\ acute\\:\\ 0\\.002805690597216084\ \(0\)\
\-\ 1\\:\\ 0\\.0027038914467549294\ \(0\)\
\-\ into\\:\\ 0\\.0027038914467549294\ \(0\)\
\-\ tissue\\:\\ 0\\.002693379239963555\ \(0\)\
\-\ without\\:\\ 0\\.002675549423348617\ \(0\)\
\-\ a\\:\\ 0\\.0026369667674109127\ \(0\)\
\-\ small\\:\\ 0\\.0026177862824217\ \(0\)\
\-\ diagnosis\\:\\ 0\\.0026093342164633243\ \(0\)\
\-\ present\\:\\ 0\\.0025665010025687244\ \(0\)\
\-\ lower\\:\\ 0\\.0025556676454306683\ \(0\)\
\-\ it\\:\\ 0\\.0025543196602832666\ \(0\)\
\-\ large\\:\\ 0\\.0024847638721157976\ \(0\)\
\-\ have\\:\\ 0\\.0024606889339961325\ \(0\)\
\-\ 2\\:\\ 0\\.0024469474687640242\ \(0\)\
\-\ \\-\\:\\ 0\\.002435809120622824\ \(0\)\
\-\ but\\:\\ 0\\.0024235416237148107\ \(0\)\
\-\ after\\:\\ 0\\.002351065429001599\ \(0\)\
\-\ female\\:\\ 0\\.0023361173822444596\ \(0\)\
\-\ presents\\:\\ 0\\.002321335499345646\ \(0\)\
\-\ treatment\\:\\ 0\\.002300022552660754\ \(0\)\
\-\ seen\\:\\ 0\\.002245515445568737\ \(0\)\
\-\ which\\:\\ 0\\.002121202908567219\ \(0\)\
\-\ that\\:\\ 0\\.00196274033053035\ \(0\)\
\-\ on\\:\\ 0\\.0019252420541633725\ \(0\)\
\-\ normal\\:\\ 0\\.0017813995406902939\ \(0\)\
\-\ as\\:\\ 0\\.0017188530663485742\ \(0\)\
\-\ \\.\\:\\ 0\\.001605032217167252\ \(0\)\
\-\ with\\:\\ 0\\.0015559065969400231\ \(0\)\
\-\ this\\:\\ 0\\.0012781079964283683\ \(0\)\
